Kilburn, L. B., Khuong-Quang, D., Hansford, J. R., Landi, D., van der Lugt, J., Leary, S. E. S., . . . Nysom, K. (2024). The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: The phase 2 FIREFLY-1 trial. Nature medicine, 30(1), . https://doi.org/10.1038/s41591-023-02668-y
Chicago-Zitierstil (17. Ausg.)Kilburn, Lindsay B., et al. "The Type II RAF Inhibitor Tovorafenib in Relapsed/refractory Pediatric Low-grade Glioma: The Phase 2 FIREFLY-1 Trial." Nature Medicine 30, no. 1 (2024). https://doi.org/10.1038/s41591-023-02668-y.
MLA-Zitierstil (9. Ausg.)Kilburn, Lindsay B., et al. "The Type II RAF Inhibitor Tovorafenib in Relapsed/refractory Pediatric Low-grade Glioma: The Phase 2 FIREFLY-1 Trial." Nature Medicine, vol. 30, no. 1, 2024, https://doi.org/10.1038/s41591-023-02668-y.